Dubai Emerges As A Regional Hub For Gene Therapy Breakthroughs: Medcare Leads The Way In Transforming Lives Of Children With Rare Genetic Diseases

Dubai is quickly establishing himself as a center for Vanguardia gene therapy, with Medcare Royal Specialty Hospital Al Qusais at the forefront of the treatment of rare genetic disorders such as spinal dystrophy (SMAD) and Duchenne. With the proximity of the Hospital to the Dubai International Airport, a growing number of patients in Türkiye and other countries in the region and beyond travel to Dubai for the treatments of life changes.

Medcarehas has redefined excellence in the field of pediatric neurology and gene -based therapies, pioneer in a new era of hope and healing for families affected by such weakening conditions. Turkish families increasingly resort to Medcare for SMA treatments, with incidence rates in Türkiye significantly higher than the global average. Hospital’s avant -garde facilities, international medical experience and holistic treatment and holistic treatment, treatment, treatment, treatment, treatment, treatment. EAU but through the Mena and Asia-Pacific regions.

The SMA, a rare neurodegenerative condition, causes progressive muscle weakness and is fatal in childhood if not. In Türkiye, the SMA affects 1 in 6,000 births compared to 1 in 10000 worldwide. According to Turkish health authorities, there are currently around 3,000 people who live with SMA, and about 150 new cases are diagnosed each year. The DMD, another severe neuromuscular disorder, affects more than 4,000 genetically confirmed patients in Türkiye.

Under the leadership of Dr. Vivek Mundada, a pediatric neurologist consultant certified by the British Board at Medcare Royal Specialty Hospital, gave notable results in the management of genetic thesis conditions. Unlike traditional therapies that require ongoing spinal injections, Medcare offers a potential healing gene therapy and once it addresses the root cause of the condition, drastically improving the quality of life and long -term health. Medcare is the first private medical care provider outside the US. To administer successful gene therapy for SMA in the Mena region, since it has delivered about 100 infusions to date at the Medcare Women & Children Hospital.

“Dubai is becoming a medical innovation center, and Medcare is proud to lead that movement, as special in the field of strange genetic diseases,” said Dr. Vivek Mundada, pediatric neurologist at Medcare Royal Specialty Hospital. “Through our comprehensive patient -centered care model, we are transforming the results for children who previously had limited treatment options.”

The Medcare approach goes beyond clinical excellence. Patients benefit from a multidisciplinary team that includes experts in neurology, pulmonology, orthopedics, rehabilitation and genetic advice. The hospital also provides continuous monitoring care for international patients after returning home.

Turkish families have already seen outstanding results. One of those stories is Mirha’s, diagnosed with SMA only nine days after she was born. In 2024, he underwent gene therapy in Medcare and is now thriving without the need to breathe or feed support. Similarly, Elif ordered who was treated in March 2024 when he was only 2 years old, he has demonstrated remarkable progress following that gene therapy in Medcare.

Mirha’s parents commented: “We cannot express enough gratitude to Dr. Mundada and the Medcare team. Thanks to the expert and compassionate care in Dubai, our daughter has been given a new opportunity for life.”

Aligned with the Eau’s vision of being a global center for innovation and medical excellence, Medcare continues to invest in infrastructure, talent and technology to sacrifice the best attention in class. The newly released unity of rare diseases at Medcare Royal Specialty Hospital in Dubai offers diagnoses with AI, Robotic Surgery and Advanced Quaternary Care, reinforcing its leadership in the management of rare diseases.

As part of Aster DM Healthcare, Medcare undertakes to expand access to advanced medical care for international patients, while contributing to the growing medical tourism sector of the EAU, where families see genetic disorders of profitable time care and profitable time care.